Weeks 48: The This Is Working Phase If youve stayed consistent, this is where many clients feel like theyve hit a groove
Disclosure of interest: None Poster Session II - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.02 - ACUTE MANAGEMENT - Thrombolysis or thrombectomy P621 - ESOC25-1482 STRATEGY FOR IMPROVING STROKE TREATMENT RESPONSE (SISTER): A PHASE-2 CLINICAL TRIAL OF TS23, A NOVEL MECHANISM FOR IMPROVING OUTCOMES IN ACUTE ISCHEMIC STROKE Eva Mistry 1 , Jordan Elm 2 , Pamela Plummer 1 , Rebeca Aragon Garcia 1 , Paul Kussie 3 , Ryan Sullivan 3 , Iris Davis 1 , Yasmin Aziz 1 , Vivek Khandwala 1 , Achala Vagal 1 , Noor Sabagha 1 , Joseph Broderick 1 , Guy Reed 3 , Pooja Khatri 1 , Scott Janis 4 1 University of Cincinnati, Cincinnati, United States, 2 Medical University of South Carolina, Charleston, United States, 3 Translational Sciences, Inc., Phoenix, United States, 4 National Institute of Neurological Disorder and Stroke, Bethesda, United States Background and Aims: Plasminogen activators for acute ischemic stroke (AIS) suffer from limitations of a narrow therapeutic window, suboptimal thrombolysis of larger clots, paradoxical microthrombosis, neurotoxic effects and hemorrhage
This opens avenues for developing small-molecule PGC-1 agonists or strategies to modulate DDIT4 as pharmacologic alternatives to cell therapy, which could circumvent the logistical and regulatory complexities associated with live cell administration
Helps manage symptoms easily at home along with dietary changes
Timing Considerations Administration timing matters with DSIP
